3 articles
Major beauty firms like Galderma and L'Oreal are developing treatments for facial volume loss linked to obesity drugs like Ozempic, with the market projected to reach $2 billion within five years.
Swiss skincare conglomerate Galderma agreed to acquire medical-grade skincare firm ZO Skin Health for approximately $1.5 billion, expanding its US market presence alongside key brands like Cetaphil an
Swiss skincare firm Galderma reported a 25.5% Q1 sales increase to $1.47 billion, driven by a 41.5% surge in US sales. The company stated it can manage upcoming US tariff impacts, including those on p
ChemBrief